Autocrine Production of Interleukin-6: A Mechanism of Interleukin-6 Independence in Dexamethasone-Resistant 7TD1 Murine Myeloma Cells


Several factors could contribute to proliferation of multiple myeloma (MM) cells independent of interleukin-6 (IL6) in the later stages of the disease. Our previous studies established a dexamethasone-resistant 7TD1 cell line (7TD1-Dxm) and have shown that one mechanism of resistance to dexamethasone is due to inhibition of cytochrome c release. We have also observed that 7TD1-Dxm cells proliferate independently of externally-added IL6. This study therefore aimed to elucidate the mechanisms responsible for IL6-independent proliferation in 7TD1-Dxm cells. Our results indicated that 7TD1-Dxm cells produced IL6 in an autocrine fashion. We have observed that dexamethasone-resistant 7TD1 cells become dexamethasone-resistant and IL6-independent for proliferation concomitantly. This strongly suggests that production of IL6 by 7TD1-Dxm cells may play an important role in the development of dexamethasone resistance. Consequently, further investigation of the molecular mechanisms responsible for IL6 production may be helpful in delineating the mechanisms leading to dexamethasone resistance.

Share and Cite:

Gangavarapu, K. , Bhushan, A. , Lai, J. and Daniels, C. (2014) Autocrine Production of Interleukin-6: A Mechanism of Interleukin-6 Independence in Dexamethasone-Resistant 7TD1 Murine Myeloma Cells. Journal of Cancer Therapy, 5, 523-530. doi: 10.4236/jct.2014.56060.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hallek, M., Bergsagel, L. and Anderson, K.C. (1998) Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process. Blood, 91, 3-21.
[2] Klein, B., Zhang, X.G., Lu, Z.H. and Bataille, R. (1995) Interleukin-6 in Human Multiple Myeloma. Blood, 85, 863-872.
[3] Hirano, T. (1991) Interleukin 6 (IL-6) and Its Receptor: Their Role in Plasma Cell Neoplasias. International Journal of Cell Cloning, 9, 166-184.
[4] Bommert, K., Bargou, R.C. and Stuhmer, T. (2006) Signalling and Survival Pathways in Multiple Myeloma. Europeam Journal of Cancer, 42, 1574-1580.
[5] Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., et al. (2004) Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report. Cancer Research, 64, 1546-1558.
[6] Bruno, B., Rotta, M., Giaccone, L., Massaia, M., Bertola, A., Palumbo, A. and Boccadoro, M. (2004) New Drugs for Treatment of Multiple Myeloma. Lancet Oncology, 5, 430-442.
[7] Hideshima, T., Chauhan, D., Richardson, P. and Anderson, K.C. (2005) Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma. Journal of Clinical Oncology, 23, 6345-6350.
[8] Kim, I., Uchiyama, H., Chauhan, D. and Anderson, K.C. (1994) Cell Surface Expression and Functional Significance of Adhesion Molecules on Human Myeloma-Derived Cell Lines. British Journal of Haematology, 87, 483-493.
[9] Potter, M. (2003) Neoplastic Development in Plasma Cells. Immunological Reviews, 194, 177-195.
[10] Lauta, V.M. (2003) A Review of the Cytokine Network in Multiple Myeloma: Diagnostic, Prognostic, and Therapeutic Implications. Cancer, 97, 2440-2452.
[11] Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., et al. (1994) Interleukin-6 Prevents Dexamethasone-Induced Myeloma Cell Death. Blood, 84, 3063-3070.
[12] Chatterjee, M., Honemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., et al. (2002) In the Presence of Bone Marrow Stromal Cells Human Multiple Myeloma Cells Become Independent of the IL-6/gp130/STAT3 Pathway. Blood, 100, 3311-3318.
[13] Frassanito, M., Cusmai, A., Iodice, G. and Dammacco, F. (2001) Autocrine Inteleukin-6 Production and Highly Malignant Multiple Myeloma: Relation with Resistance to Drug-Induced Apoptosis. Blood, 97, 483-489.
[14] Kyle, R.A. (2001) Management of Patients with Multiple Myeloma: Emphasizing the Role of High-Dose Therapy. Clinical Lymphoma, 2, 21-28.
[15] Gangavarapu, K.J., Olbertz, J.L., Bhushan, A., Lai, J.C.K. and Daniels, C.K. (2008) Apoptotic Resistance Exhibited by Dexamethasone-Resistant Murine 7TD1 Cells Is Controlled Independently of Interleukin-6 Triggered Signaling. Apoptosis, 13, 1394-1400.
[16] Gangavarapu, K.J., Bhushan, A., Lai, J.C.K. and Daniels, C.K. (2013) Differential Regulation of Cytochrome c Release in Dexamethasone-Resistant 7TD1 Cells. Journal of Cancer Therapy, 4, 835-842.
[17] Liu, T., Fei, Z., Gangavarapu, K.J., Agbenowu, S., Bhushan, A., Lai, J.C.K., et al. (2013) Interleukin-6 and JAK2/ STAT3 Signaling Mediate the Reversion of Dexamethasone Resistance after Dexamethasone Withdrawal in 7TD1 Multiple Myeloma Cells. Leukemia Research, 37, 1322-1328.
[18] Irvin, B.J., Hanson, C.L., Smith, L.H., Daniels, C.K. (2001) Cyclic AMP- and IL6-Signaling Cross Talk: Comodulation of Proliferation and Apoptosis in the 7TD1 B Cell Hybridoma. Experimental Cell Research, 265, 73-79.
[19] Gangavarapu, K.J. (2008) Characterization of a Dexamethasone-Resistant 7TD1 Murine Myeloma Cell Line. Ph.D. Dissertation, Idaho State University, Pocatello.
[20] Mosmann, T. (2001) Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. Journal of Immunological Methods, 65, 55-63.
[21] Egan, J.B., Shi, C.X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., et al. (2012) Whole Genome Sequencing of Multiple Myeloma from Diagnosis to Plasma Cell Leukemia Reveals Genomic Initiating Events, Evolution and Clonal Tides. Blood, 120, 1060-1066.
[22] Keats, J.J., Chesi, M., Egan, J.B., Garbitt, V.M., Palmer, S.E., Braggio, E., et al. (2012) Clonal Competition with Alternating Dominance in Multiple Myeloma. Blood, 120, 1067-1076.
[23] Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., et al. (1988) Autocrine Generation and Requirement of BSF-2/IL-6 for Human Multiple Myelomas. Nature, 332, 83-85.
[24] Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., et al. (1989) Paracrine Rather Than Autocrine Regulation of Myeloma Cell Growth and Differentiation by Interleukin-6. Blood, 73, 517-523.
[25] Jourdan, M., Mahtouk, K., Veyrune, J.L., Couderc, G., Fiol, G., Redal, N., et al. (2005) Delineation of the Roles of Paracrine and Autocrine Interleukin-6 (IL-6) in Myeloma Cell Lines in Survival versus Cell Cycle. A Possible Model for the Cooperation of Myeloma Cell Growth Factors. European Cytokine Network, 16, 57-64.
[26] Bohnhorst, J., Rasmussen, T., Moen, S.H., Flottum, M., Knudsen, L., Borset, M., et al. (2006) Toll-Like Receptors Mediate Proliferation and Survival of Multiple Myeloma Cells. Leukemia, 20, 1138-1144.
[27] Yang, Y., Groshong, J.S., Matta, H., Gopalakrishnan, R., Yi, H. and Chaudhary, P.M. (2011) Constitutive NF-kappaB Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells. Journal of Biological Chemistry, 286, 27988-27997.
[28] Verdelli, D., Nobili, L., Todoerti, K., Mosca, L., Fabris, S., D’Anca, M., et al. (2014) Molecular events Underlying Interleukin-6 Independence in a Subclone of the CMA-03 Multiple Myeloma Cell Line. Genes Chromosomes Cancer, 53, 154-167.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.